News

A form of T-cell (non-Hodgkin) lymphoma known as breast implant associated anaplastic large-cell lymphoma (BIA-ALCL) has been noted as a rare association with the implant-based approach of reconstructive surgery post mastectomy.

The Environmental Working Group has issued published its 11th annual guide including information on beach and sport sunscreens, moisturizers and lip products containing Sun Protection Factor (SPF).

The FDA has granted approval to the second generation ALK-inhibitor, ceritinib for treatment of patients with ALK-positive, metastatic non-small cell lung cancer (NSCLC).

A recent study provides more evidence toward the link between electronic cigarette use and bladder cancer risk.

IBM Watson Health, Cota and Hackensack Meridian Health have joined together to help oncologists make evidence- and outcomes-based clinical decisions for their cancer patients, which could reduce total cost of care.

Pembrolizumab (Keytruda) has been granted accelerated approval for certain solid tumors.

Members of the ACCC have created an online course, Financial Advocacy Boot Camp, to help financial navigators find the funds for their patients.

Overall survival for patient with cutaneous melanoma was significantly lower for non-white patients, indicating a need for more emphasis on screening and awareness in these populations.

More Stage I cancers were diagnosed after the passage of the Affordable Care Act (ACA), also known as Obamacare, within five screenable disease types: colorectal cancer, female breast cancer, cervical cancer, lung cancer, and prostate cancer).

The FDA has granted approval to pembrolizumab (Keytruda) for the treatment of patients with locally advanced or metastatic urothelial carcinoma.

The human papillomavirus (HPV) vaccine has reduced the prevalence of high-risk oral HPV infections by 88& in young adults that have had at least 1 dose of the vaccine.

Eating tree nuts may improve overall survival and reduce the risk of recurrence in patients with colon cancer.

A recent analysis showed that many women within the recommended age for routine screening are not up to date on Pap tests.

A recent study has found that, when it comes to physical activity recommendations, there is a disparity between what patients want and what their providers do.

Researchers found that tai chi chih, including guided movement and meditation, may be helpful in reducing insomnia experienced by breast cancer survivors.

For asymptomatic adults, the US Preventive Services Task Force (USPSTF) recommends against screening for thyroid cancer.

The FDA has granted an accelerated approval to pembrolizumab (Keytruda) for use in combination with pemetrexed plus carboplatin as a frontline treatment for patients with non-small cell lung cancer (NSCLC).

Expert Oncology Nurses to Lead Inaugural Conference.

The FDA has approved the co-packaging of oral medication ribociclib and letrozole, used to treat HR-positive, HER2-negative advanced breast cancer in postmenopausal women.

The FDA has granted accelerated approval to avelumab (Bavencio) for the treatment of patients with locally advanced or metastatic urothelial carcinoma.

At the 2017 ONS Annual Congress, nurses from John Hopkins Sidney Kimmel Cancer Center reported on their study involving vincristine infused via minibag infusions.

The revised American Health Care Act has passed through the House of Representatives.

At the 2017 Community Oncology Alliance annual conference, panelists discussed techniques to encourage improved adherence in patients on oral oncology medication.

ASCO has updated their guidance on the use of second-line hormonal therapy for chemotherapy-naive patients with castration-resistant prostrate cancer (CRPC).

A recent trial is evaluating a new drug to treat cachexia, testing its efficacy in dogs currently.

The FDA has granted accelerated approval for the PD-L1 inhibitor durvalumab for the treatment of locally advanced or metastatic urothelial carcinoma.

Seven professional organizations came together to issue a new position statment on recommendations for treating patients with aromatase-inhibitor-related bone loss (AIBL).

The FDA has granted accelerated approval to brigatinib for patients with metastatic ALK-positive non-small cell lung cancer (NSCLC) resistant to prior crizotinib (Xalkori).

A recent study indicates that the use of bilateral mastectomy to treat women with ductal carcinoma in situ is unnecessary.